Ultomiris® (ravulizumab-cwvz)
for Paroxysmal Nocturnal Hemoglobinuria
Ultomiris (ravulizumab-cwvz) is approved for treating generalized myasthenia gravis (gMG) in adults who are anti-AChR antibody-positive, paroxysmal nocturnal hemoglobinuria (PNH) in adults and children 1+, atypical hemolytic uremic syndrome (aHUS) in adults and children 1+, and neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-AQP4 antibody-positive. It works by inhibiting C5, a protein in the complement system, preventing immune attacks on healthy cells and reducing disease progression.
